FREE Alzheimer's Prescreening TRAVELLER Test for 50 to 90 years old

New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology. Honolulu, Hawaii 2025 August



According to Roche, "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires (I) early detection and (II) effective therapeutics.

Early detection:

Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. The potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology. Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families. The test, which received Breakthrough Device Designation from the U.S. FDA 2024, will be utilized in Roche's TRONTIER studies to be carried out in multiple sites including Hawaii Memory Dis. Center and Alzheimer's Research Unit.


Hawaii Alzheimer's Specialists & Researchers

Effective Therapeutics:

Current approved monoclonal antibodies like Leqembi and donanemab have shown an ability to slow the disease's decline, but the effects on Alzheimer's progression are modest and come with side effects, most notably swelling or bleeding in brain or ARIA (Amyloid Related Imaging Abnormalities). Insurers are still hesitant to cover their high costs. Roche's experimental Alzheimer's disease drug trontinemab showed "best-in-class" potential based on its ability to quickly clear clumps of amyloid protein from the brains. Roche uses a type of novel delivery technology that's meant to more easily deliver medicines to the brain via active TfR1 mediated transcytosis at the capillary level. Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5%. Phase III TRONTIER studies in early symptomatic Alzheimer's disease will take place in Hawaii in late 2025.

A pre-screening study, **TRAVELLER,** based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has already begun in Hawaii July 2025.

For a FREE Alzheimer's Screening Elecsys pTau217 test, Call Hawaii Memory Dis Center & Alzheimer's Research Unit **(808) 564-6141 for more information or info@HawaiiNeuroscience.com**